Accordingly, the addition of cetuximab to encorafenib had a synergistic anti-proliferative effect in a human xenograft model of BRAF-mt CRC.27 In a pilot trial of 15 patients with BRAF-mt mCRC, the combination of vemurafenib and panitumumab induced modest anti-tumour activity. Here, BRAF is linked to colorectal carcinoma.